Anthony G. Quinn, President & CEO at Aeglea BioTherapeutics, Inc. (AGLE), bought 18,713 shares at $6.76 ($126K) on 2019-05-15, disclosed to the SEC on 2019-05-17.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $7.10 | 719 | $5K | 4.0% |
| 2 | $6.76 | 6,256 | $42K | 33.4% |
| 3 | $6.83 | 5,520 | $38K | 29.8% |
| 4 | $6.65 | 6,218 | $41K | 32.7% |
| Total | $6.76 avg | 18,713 | $126K | 100% |
| Filing → |
| AGLE | BUY | 2022-03-18 | $375K | — | Filing → |
| AGLE | BUY | 2022-03-15 | $562K | — | Filing → |
| AGLE | BUY | 2021-12-13 | $358K | — | Filing → |